Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new anesthesia drug may keep blood pressure steadier during liver surgery

NCT ID NCT07789275

Disease control Sponsor: Beijing Tsinghua Chang Gung Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether remimazolam, an intravenous anesthetic, prevents low blood pressure better than propofol during major liver surgery. Adults having at least three liver segments removed will receive one of the two drugs to maintain anesthesia. Researchers will measure how low blood pressure drops and how long it stays low, and they will also track bleeding, transfusions, recovery, and complications. The goal is to see if remimazolam offers a safer anesthesia option for this high-risk surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remimazolam
What this could lead to
If remimazolam works, it could offer a safer anesthesia option for major liver surgery, reducing the risk of low blood pressure and its complications.
What could go wrong
This is a single-center trial, and results may not apply to all patients. Remimazolam may not outperform propofol, and any anesthesia carries risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 224 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 85 years * Scheduled for elective liver resection * Preoperative surgical plan includes resection of at least three Couinaud liver segments * Planned use of low central venous pressure management, general anesthesia, invasive arterial pressure monitoring, and central venous pressure monitoring * American Society of Anesthesiologists physical status II or III * Both study anesthesia strategies are considered clinically appropriate * Able to understand the study information and provide written informed consent Exclusion Criteria: * Emergency surgery or inability to complete written informed consent before surgery * Known contraindication or serious hypersensitivity to remimazolam, another benzodiazepine, propofol, or a relevant excipient * Preoperative shock, ongoing vasoactive drug support, or another hemodynamically unstable condition that makes either study anesthesia strategy unsafe * Child-Pugh class C, Model for End-Stage Liver Disease score of 20 or higher, or end-stage liver disease in the investigator's judgment * Massive ascites, recent variceal bleeding, clinically important hypersplenism with severe thrombocytopenia, or portal hypertension sufficient to substantially alter circulatory management * Regular long-term benzodiazepine use, drug dependence, or alcohol misuse expected to affect the pharmacological evaluation * Clinical requirement for an inhalational anesthetic or another maintenance anesthesia strategy incompatible with randomized assignment * Pregnant or breastfeeding * Concurrent participation in another interventional study that may affect the primary outcome * Any other condition that, in the investigator's judgment, makes participation unsafe or prevents completion of the study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatectomy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatectomy Intraoperative hypotension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, 102218, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.